Does blockade of the CD40-CD40L pathway reduce T and B cell mediated alloreactivity after kidney transplantation?
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
orgaantransplantatie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Number and characteristics of effector and regulatory T-, and B- cells and
dendritic cells (DC), T and B cell interaction and cytokine production and
effectiveness of CFZ533 to block CD40 expression will be studied. If a renal
biopsy is performed in the main study (MEC-2018-138), the cellular infiltrate
will also be characterized with additional markers focused on the
CD40-CD40L(CD154) axis.
Secondary outcome
n/a
Background summary
The immunologic effect of the new anti-CD40 antibody CFZ533 (iscalimab) are not
known.
Study objective
Does blockade of the CD40-CD40L pathway reduce T and B cell mediated
alloreactivity after kidney transplantation?
Study design
Observational study. In patients participating in the main study (MEC 2018-138)
blood samples will be taken for extensive immunological assessments at given
time points.
Study burden and risks
No risk nor benefit. This study is a lab study, for which blood will be taken
from participating patients. If a renal biopsy is performed in the main study,
additional immunological test will be performed on that biopsy.
Dr. Molenwaterplein 40
Rotterdam 3015 GD
NL
Dr. Molenwaterplein 40
Rotterdam 3015 GD
NL
Listed location countries
Age
Inclusion criteria
All patients participating in the main trial (MEC 2018-138)
Exclusion criteria
None
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL67950.078.18 |